Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study

Marie Skougaard, Tanja S Jørgensen, Mia J Jensen, Christine Ballegaard, Jørgen Guldberg-Møller, Alexander Egeberg, Robin Christensen, Peter Benzin, Zara R Stisen, Joseph F Merola, Laura C Coates, Vibeke Strand, Phillip Mease, Lars Erik Kristensen, Marie Skougaard, Tanja S Jørgensen, Mia J Jensen, Christine Ballegaard, Jørgen Guldberg-Møller, Alexander Egeberg, Robin Christensen, Peter Benzin, Zara R Stisen, Joseph F Merola, Laura C Coates, Vibeke Strand, Phillip Mease, Lars Erik Kristensen

Abstract

Objective: The objective was to investigate interplay and physical and mental component scores between change (Δ) in health-related quality of life (HRQoL) quantified by the physical component score (PCS) and mental component score (MCS) retrieved from short-form health survey (SF-36), change in disease activity (ΔDAS28CRP) and manifestations of PsA.

Methods: PsA patients initiating new medical therapy were enrolled. Independent disease measures evaluating disease activity, enthesitis, psoriasis, pain and fatigue were collected at treatment initiation and after 4 months. Interplay between independent disease measures and dependent outcome measures, ΔPCS and ΔMCS, was described with univariate regression analyses. Multivariate regression analyses were applied to assess the impact of independent variables, such as individual disease outcome measures vs ΔDAS28CRP on ΔPCS and ΔMCS.

Results: One hundred and eight PsA patients were included. In the univariate regression analyses, improvement in fatigue, pain and disability were associated with improvement in ΔPCS (β; -2.08, -0.18 and -13.00, respectively; all P < 0.001) and ΔMCS (β; -1.59, -0.12 and -6.07, respectively; P < 0.001, P < 0.001 and P = 0.003, respectively). When patient-reported outcomes were included in the final multivariate models, improvements in ΔPCS and ΔMCS were associated with improvements in pain, fatigue and disability (P < 0.001). Improvement in enthesitis impacted ΔPCS positively (β -0.31, P < 0.001). No association was found between change in skin psoriasis, ΔPCS and ΔMCS (β 0.15, P = 0.056 and β 0.05, P = 0.561, respectively).

Conclusion: In this PsA patient cohort, diminishing pain, disability and fatigue improved PCS and MCS significantly. Changes in enthesitis and psoriasis did not grossly impact HRQoL compared with DAS28CRP. Individual PsA manifestations influence HRQoL differently, which is important clinically when targeting treatment.

Trial registration: ClinicalTrials.gov, https://ichgcp.net/clinical-trials-registry/NCT02572700" title="See in ClinicalTrials.gov">NCT02572700.

Keywords: DAS28CRP; PsA; enthesitis; fatigue; health-related quality of life; pain; psoriasis.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Patient inclusion flow chart Data were included from the PIPA cohort study [19]. aPatients were screened for eligibility by initial interviews at departments of rheumatology or by telephone and later clinical assessment. bInclusion criteria included age ≥18 years, diagnosed with PsA fulfilling the CASPAR criteria, presenting with peripheral joint involvement and about to initiate a new conventional synthetic DMARD or biological DMARD treatment course. Data were retrieved on 18 November 2020 from the consecutive cohort.
Fig . 2
Fig. 2
SF-36 spydergram for PsA patients before and 4 months after treatment compared with Danish SF-36 normative data Mean SF-36 scores at baseline (yellow) and 4 months follow-up (blue) and Danish normative data (green). BP: bodily pain; GH: general health; MH: mental health; PF: physical functioning; RE: role emotional; RP: role physical; SF: social functioning; VT: vitality.
Fig . 3
Fig. 3
3D associations between change in specific individual disease outcome measures, ΔDAS28CRP and change in physical and mental component scores Three-dimensional associations between outcome measures from baseline to follow-up (ΔDAS28CRP and ΔPCS/ΔMCS) and ΔPsAID fatigue (A), ΔVAS pain (B), ΔSPARCC (C) and ΔPASI (D), respectively, presented in xyz plots, with blue arrows indicating positive change and red arrows negative change from baseline to follow-up. The green and blue regression planes represent ΔPCS- and ΔMCS-related data, respectively. DAS28CRP: DAS for 28 joints and CRP; MCS: mental component score; PASI: Psoriasis Area Severity Index; PCS: physical component score; PsAID: PsA impact of disease; SPARCC: Spondyloarthritis Research Consortium of Canada enthesitis index; VAS: visual analog scale.

References

    1. Egeberg A, Kristensen LE, Thyssen JP. et al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis 2017;76:1591–7.
    1. Kristensen LE, Englund M, Neovius M. et al. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis 2013;72:1675–9.
    1. Kristensen LE, Jørgensen TS, Christensen R. et al. Societal costs and patients’ experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis 2017;76:1495–501.
    1. Alinaghi F, Calov M, Kristensen LE. et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019;80:251–65.e19.
    1. Gudu T, Gossec L.. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol 2018;14:405–17.
    1. Furst DE, Tran M, Sullivan E. et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol 2017;36:2045–54.
    1. Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD.. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res 2015;67:264–72.
    1. Van De Kerkhof PCM, Reich K, Kavanaugh A. et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatology Venereol 2015;29:2002–10.
    1. Orbai A-M, Mease PJ, de Wit M. et al. Report of the GRAPPA-OMERACT psoriatic arthritis working group from the GRAPPA 2015 annual meeting. J Rheumatol 2016;43:965–9.
    1. Orbai AM, De Wit M, Mease PJ. et al. Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J Rheumatol 2017;44:1522–8.
    1. Husted JA, Gladman DD, Farewell VT, Cook RJ.. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001;45:151–8.
    1. Rosen CF, Mussani F, Chandran V. et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 2012;51:571–6.
    1. Carneiro C, Chaves M, Verardino G. et al. Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. Clin Cosmet Investig Dermatol 2017;10:155–63.
    1. Skougaard M, Jørgensen TS, Rifbjerg-Madsen S. et al. Relationship between fatigue and inflammation, disease duration, and chronic pain in psoriatic arthritis: an observational DANBIO registry study. J Rheumatol 2020;47:548–52.
    1. Owczarek K, Jaworski M.. Quality of life and severity of skin changes in the dynamics of psoriasis. Adv Dermatology Allergol 2016;2:102–8.
    1. Honma M, Cai Z, Burge R. et al. Relationship between rapid skin clearance and quality of life benefit: post hoc analysis of Japanese patients with moderate-to-severe psoriasis treated with ixekizumab (UNCOVER-J). Dermatol Ther (Heidelb) 2020;10:1397–404.
    1. Smolen JS, Schöls M, Braun J. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.
    1. Reygaerts T, Mitrovic S, Fautrel B, Gossec L.. Effect of biologics on fatigue in psoriatic arthritis: a systematic literature review with meta-analysis. Jt Bone Spine 2018;85:405–10.
    1. Højgaard P, Christensen R, Dreyer L. et al. Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study. BMJ Open 2016;6:e010650.
    1. Taylor W, Gladman D, Helliwell P. et al.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
    1. Bjorner JB, Thunedborg K, Kristensen TS, Modvig J, Bech P.. The Danish SF-36 health survey. J Clin Epidemiol 1998;51:991–9.
    1. Ware JE. SF-36 Health Survey update. Spine (Phila Pa 1976) 2000;25:3130–9.
    1. Lins L, Carvalho FM.. SF-36 total score as a single measure of health-related quality of life: scoping review. SAGE Open Med 2016;4:2050312116671725.
    1. Bruce B, Fries JF.. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 23(5 Suppl 39):S14–8.
    1. Price DD, McGrath PA, Rafii A, Buckingham B.. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:45–56.
    1. Gossec L, De Wit M, Kiltz U. et al.; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012–9.
    1. Bjorner JB, Damsgaard MT Watt T, Beck P. et al. Dansk manual til SF-36: et spørgeskema om helbredsstatus [Danish SF-36 manual: a questionnaire on health status]. Lægemiddelindustriforeningen 1997;1:70–140.
    1. Strand V, Sharp V, Koenig AS. et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143–50.
    1. Ljosaa TM, Mork C, Stubhaug A, Moum T, Wahl AK.. Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. J Eur Acad Dermatology Venereol 2012;26:29–35.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever